188 related articles for article (PubMed ID: 30471851)
21. Evaluation of NSD2 and NSD3 in overgrowth syndromes.
Douglas J; Coleman K; Tatton-Brown K; Hughes HE; Temple IK; Cole TR; Rahman N;
Eur J Hum Genet; 2005 Feb; 13(2):150-3. PubMed ID: 15483650
[TBL] [Abstract][Full Text] [Related]
22. Targeting the Nuclear Receptor-Binding SET Domain Family of Histone Lysine Methyltransferases for Cancer Therapy: Recent Progress and Perspectives.
Shrestha A; Kim N; Lee SJ; Jeon YH; Song JJ; An H; Cho SJ; Kadayat TM; Chin J
J Med Chem; 2021 Oct; 64(20):14913-14929. PubMed ID: 34488340
[TBL] [Abstract][Full Text] [Related]
23. Identification of Novel Potent NSD2-PWWP1 Ligands Using Structure-Based Design and Computational Approaches.
Carlino L; Astles PC; Ackroyd B; Ahmed A; Chan C; Collie GW; Dale IL; O'Donovan DH; Fawcett C; di Fruscia P; Gohlke A; Guo X; Hao-Ru Hsu J; Kaplan B; Milbradt AG; Northall S; Petrović D; Rivers EL; Underwood E; Webb A
J Med Chem; 2024 Jun; 67(11):8962-8987. PubMed ID: 38748070
[TBL] [Abstract][Full Text] [Related]
24. The methyltransferase NSD3 has chromatin-binding motifs, PHD5-C5HCH, that are distinct from other NSD (nuclear receptor SET domain) family members in their histone H3 recognition.
He C; Li F; Zhang J; Wu J; Shi Y
J Biol Chem; 2013 Feb; 288(7):4692-703. PubMed ID: 23269674
[TBL] [Abstract][Full Text] [Related]
25. Backbone resonance assignments for the SET domain of the human methyltransferase NSD2.
Bobby R; Peciak K; Milbradt AG
Biomol NMR Assign; 2016 Oct; 10(2):307-10. PubMed ID: 27368234
[TBL] [Abstract][Full Text] [Related]
26. NSD2 links dimethylation of histone H3 at lysine 36 to oncogenic programming.
Kuo AJ; Cheung P; Chen K; Zee BM; Kioi M; Lauring J; Xi Y; Park BH; Shi X; Garcia BA; Li W; Gozani O
Mol Cell; 2011 Nov; 44(4):609-20. PubMed ID: 22099308
[TBL] [Abstract][Full Text] [Related]
27. NSD2 contributes to oncogenic RAS-driven transcription in lung cancer cells through long-range epigenetic activation.
García-Carpizo V; Sarmentero J; Han B; Graña O; Ruiz-Llorente S; Pisano DG; Serrano M; Brooks HB; Campbell RM; Barrero MJ
Sci Rep; 2016 Sep; 6():32952. PubMed ID: 27604143
[TBL] [Abstract][Full Text] [Related]
28. NSD2 as a Promising Target in Hematological Disorders.
Azagra A; Cobaleda C
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232375
[TBL] [Abstract][Full Text] [Related]
29. The histone methyltransferase and putative oncoprotein MMSET is overexpressed in a large variety of human tumors.
Hudlebusch HR; Santoni-Rugiu E; Simon R; Ralfkiær E; Rossing HH; Johansen JV; Jørgensen M; Sauter G; Helin K
Clin Cancer Res; 2011 May; 17(9):2919-33. PubMed ID: 21385930
[TBL] [Abstract][Full Text] [Related]
30. NSD family proteins: Rising stars as therapeutic targets.
He L; Cao Y; Sun L
Cell Insight; 2024 Apr; 3(2):100151. PubMed ID: 38371593
[TBL] [Abstract][Full Text] [Related]
31. Histone and DNA binding ability studies of the NSD subfamily of PWWP domains.
Zhang M; Yang Y; Zhou M; Dong A; Yan X; Loppnau P; Min J; Liu Y
Biochem Biophys Res Commun; 2021 Sep; 569():199-206. PubMed ID: 34271259
[TBL] [Abstract][Full Text] [Related]
32. Screening for histone codebreakers.
Bedford MT
J Biol Chem; 2018 Aug; 293(35):13766-13767. PubMed ID: 30171150
[TBL] [Abstract][Full Text] [Related]
33. NSD3, a member of nuclear receptor-binding SET domain family, is a potential prognostic biomarker for pancreatic cancer.
Xiong Q; Zhou Y; Zhang S; Zhang Y; Xu Y; Yang Y; Zhou C; Zeng Z; Han J; Zhu Q
Cancer Med; 2023 May; 12(9):10961-10978. PubMed ID: 37062069
[TBL] [Abstract][Full Text] [Related]
34. Covalent inhibition of NSD1 histone methyltransferase.
Huang H; Howard CA; Zari S; Cho HJ; Shukla S; Li H; Ndoj J; González-Alonso P; Nikolaidis C; Abbott J; Rogawski DS; Potopnyk MA; Kempinska K; Miao H; Purohit T; Henderson A; Mapp A; Sulis ML; Ferrando A; Grembecka J; Cierpicki T
Nat Chem Biol; 2020 Dec; 16(12):1403-1410. PubMed ID: 32868895
[TBL] [Abstract][Full Text] [Related]
35. SMARCA2 Is a Novel Interactor of NSD2 and Regulates Prometastatic
Chong PSY; Chooi JY; Lim JSL; Toh SHM; Tan TZ; Chng WJ
Cancer Res; 2021 May; 81(9):2332-2344. PubMed ID: 33602783
[TBL] [Abstract][Full Text] [Related]
36. The NSD2/WHSC1/MMSET methyltransferase prevents cellular senescence-associated epigenomic remodeling.
Tanaka H; Igata T; Etoh K; Koga T; Takebayashi SI; Nakao M
Aging Cell; 2020 Jul; 19(7):e13173. PubMed ID: 32573059
[TBL] [Abstract][Full Text] [Related]
37. Posttranslational modification of Aurora A-NSD2 loop contributes to drug resistance in t(4;14) multiple myeloma.
Jiang H; Wang Y; Wang J; Wang Y; Wang S; He E; Guo J; Xie Y; Wang J; Li X; Peng Z; Wang M; Hou J; Liu Z
Clin Transl Med; 2022 Apr; 12(4):e744. PubMed ID: 35389552
[TBL] [Abstract][Full Text] [Related]
38. Discovery of LLC0424 as a Potent and Selective
Liu L; Parolia A; Liu Y; Hou C; He T; Qiao Y; Eyunni S; Luo J; Li C; Wang Y; Zhou F; Huang W; Ren X; Wang Z; Chinnaiyan AM; Ding K
J Med Chem; 2024 May; 67(9):6938-6951. PubMed ID: 38687638
[TBL] [Abstract][Full Text] [Related]
39. Mutation spectra of histone methyltransferases with canonical SET domains and EZH2-targeted therapy.
Katoh M
Epigenomics; 2016 Feb; 8(2):285-305. PubMed ID: 26411517
[TBL] [Abstract][Full Text] [Related]
40. Nucleosome Binding Alters the Substrate Bonding Environment of Histone H3 Lysine 36 Methyltransferase NSD2.
Poulin MB; Schneck JL; Matico RE; Hou W; McDevitt PJ; Holbert M; Schramm VL
J Am Chem Soc; 2016 Jun; 138(21):6699-702. PubMed ID: 27183271
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
